Systemic Inflammatory Pattern of Patients With Community-Acquired Pneumonia With and Without COPD

被引:61
作者
Crisafulli, Ernesto [1 ]
Menendez, Rosario [2 ]
Huerta, Arturo [3 ]
Martinez, Raquel [2 ]
Montull, Beatriz [2 ]
Clini, Enrico [1 ]
Torres, Antoni [3 ]
机构
[1] Univ Modena & Reggio Emilia, Osped Villa Pineta, Dept Pulm Rehabil, Modena, Italy
[2] CIBERES, Hosp Univ & Politecnico La Fe, Serv Neumol, Valencia, Spain
[3] Univ Barcelona, Dept Pneumol, Hosp Clin Barcelona, Clin Inst Thorax,Inst Invest Biomed August Pi & S, Barcelona, Spain
关键词
OBSTRUCTIVE PULMONARY-DISEASE; TREATMENT FAILURE; RISK-FACTORS; PROCALCITONIN; PHAGOCYTOSIS; PREDICTION; BIOMARKERS; MORTALITY; SEVERITY; ACTIVATION;
D O I
10.1378/chest.12-1684
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Several clinical studies have evaluated the role of COPD in patients with community-acquired pneumonia (CAP). We investigated the systemic inflammatory response of patients with CAP (CAP + COPD) and patients without associated COPD (CAP only). Methods: Clinical, microbiologic, and immunologic data were collected from 367 prospective patients on admission to hospital during a 3-year period. Comparative analyses were performed between patients with CAP + COPD (n = 117) and those with CAP only (n = 250) and between patients with and without domiciliary use of inhaled corticosteroids (ICSs) and oral corticosteroids. Results: Detailed characteristics of clinical severity and prognosis (mortality on hospitalization and at 30 and 90 days) were similar between the CAP + COPD and CAP-only groups. The readmission rate and the frequency of previous pneumonia were higher in the group of patients with CAP + COPD. On day 1 (admission to hospital), patients with CAP + COPD had significantly lower serum levels of tumor necrosis factor-alpha, IL-1, and IL-6 compared with the CAP-only group; levels of the remaining inflammatory biomarkers (C-reactive protein, procalcitonin, IL-8, and IL-10) were similar at days 1 and 3. The exclusion of patients with domiciliary use of ICS and oral corticosteroids confirmed lower levels of TNF-alpha on day 1 in patients with CAP + COPP. Finally, lower levels of IL-6 were found only among those patients with COPD who were currently using ICS. Conclusions: Our prospective study demonstrates a different, disease-specific, early inflammatory pattern between patients with CAP with and without associated COPD. These findings are not completely corticosteroid mediated. CHEST 2013; 143(4):1009-1017
引用
收藏
页码:1009 / 1017
页数:9
相关论文
共 42 条
  • [21] Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients
    Liapikou, A.
    Polverino, E.
    Ewig, S.
    Cilloniz, C.
    Marcos, M. A.
    Mensa, J.
    Bello, S.
    Martin-Loeches, I.
    Menendez, R.
    Torres, A.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (04) : 855 - 861
  • [22] Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
    Lim, WS
    van der Eerden, MM
    Laing, R
    Boersma, WG
    Karalus, N
    Town, GI
    Lewis, SA
    Macfarlane, JT
    [J]. THORAX, 2003, 58 (05) : 377 - 382
  • [23] Markers of treatment failure in hospitalised community acquired pneumonia
    Menendez, R.
    Cavalcanti, M.
    Reyes, S.
    Mensa, J.
    Martinez, R.
    Marcos, M. A.
    Filella, X.
    Niederman, M.
    Torres, A.
    [J]. THORAX, 2008, 63 (05) : 447 - 452
  • [24] Risk factors of treatment failure in community acquired pneumonia:: implications for disease outcome
    Menéndez, R
    Torres, A
    Zalacaín, R
    Aspa, J
    Villasclaras, JJM
    Borderías, L
    Moya, JMB
    Ruiz-Manzano, J
    de Castro, FR
    Blanquer, J
    Pérez, D
    Puzo, C
    Gascón, FS
    Gallardo, J
    Alvarez, C
    Molinos, L
    [J]. THORAX, 2004, 59 (11) : 960 - 965
  • [25] Stability in community-acquired pneumonia: one step forward with markers?
    Menendez, R.
    Martinez, R.
    Reyes, S.
    Mensa, J.
    Polverino, E.
    Filella, X.
    Esquinas, C.
    Martinez, A.
    Ramirez, P.
    Torres, A.
    [J]. THORAX, 2009, 64 (11) : 987 - 992
  • [26] Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia
    Menendez, R.
    Martinez, R.
    Reyes, S.
    Mensa, J.
    Filella, X.
    Marcos, M. A.
    Martinez, A.
    Esquinas, C.
    Ramirez, P.
    Torres, A.
    [J]. THORAX, 2009, 64 (07) : 587 - 591
  • [27] Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease
    Molinos, L.
    Clemente, M. G.
    Miranda, B.
    Alvarez, C.
    del Busto, B.
    Cocina, B. R.
    Alvarez, F.
    Gorostidi, J.
    Orejas, C.
    [J]. JOURNAL OF INFECTION, 2009, 58 (06) : 417 - 424
  • [28] Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia:: a pilot study
    Montón, C
    Ewig, S
    Torres, A
    El-Ebiary, M
    Filella, X
    Rañó, A
    Xaubet, A
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (01) : 218 - 220
  • [29] The natural history of community-acquired pneumonia in COPD patients: A population database analysis
    Muellerova, Hana
    Chigbo, Chuba
    Hagan, Gerry W.
    Woodhead, Mark A.
    Miravitlles, Marc
    Davis, Kourtney J.
    Wedzicha, Jadwiga A.
    [J]. RESPIRATORY MEDICINE, 2012, 106 (08) : 1124 - 1133
  • [30] Novel nonantibiotic therapies for pneumonia - Cytokines and host defense
    Nelson, S
    [J]. CHEST, 2001, 119 (02) : 419S - 425S